Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 8 (10) , 845-854
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
- AstraZeneca
- AstraZeneca
This publication has 28 references indexed in Scilit:
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialThe Lancet Diabetes & Endocrinology, 2019
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsCirculation, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic RegistryDiabetes Care, 2015
- Impact of HbA1c, Followed From Onset of Type 1 Diabetes, on the Development of Severe Retinopathy and Nephropathy: The VISS Study (Vascular Diabetic Complications in Southeast Sweden)Diabetes Care, 2014
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: OverviewDiabetes Care, 2013
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 DiabetesAnnals of Internal Medicine, 2013
- Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' DurationArchives of internal medicine (1960), 2009